Takeda Pharma subsidiary Takeda America
Holdings, Inc. is set to acquire Philadelphia-based URL Pharma for US$800
million.
Takeda
Pharmaceutical Company Limited’s wholly-owned subsidiary, Takeda America
Holdings, Inc. is set to acquire Philadelphia-based URL Pharma for US$800
million and future performance-based contingent earn out payments.
URL
Pharma is a pharmaceutical company with 2011 calendar year revenues of nearly
$600 million. Its leading product is Colcrys (colchicine) – used to treat and
prevent gout flares. Net sales for Colcrys in calendar year 2011 were more than
$430 million, and continued growth of Colcrys sales is expected through the
product’s lifecycle.
Upon
completion of the acquisition, URL Pharma will be managed by Takeda
Pharmaceuticals U.S.A., Inc.
“This
acquisition expands Takeda’s gout treatment portfolio and leverages our
expertise in primary care,” said Douglas Cole, president, Takeda
Pharmaceuticals U.S.A., Inc.
“Gout
affects more than eight million Americans, and the prevalence of gout is
rising. We are pleased to have URL Pharma’s Colcrys added to our product
portfolio and look forward to further realizing our goal of helping patients by
providing multiple treatment options to manage the symptoms of acute and
chronic gout in the U.S.”
Colcrys
complements Takeda’s position in the gout marketplace with Uloric (febuxostat),
used to lower blood uric acid levels in adults with gout.
Source: Takeda
Pharmaceutical Co.
Business & Investment Opportunities
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Strategy, Investment and Management, focusing Healthcare and Life Science with expertise in ASEAN. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programmes. Many thanks for visiting www.yourvietnamexpert.com and/or contacting us at contact@yourvietnamexpert.com
No comments:
Post a Comment